Abstract: The invention provides MurE polypeptides and DNA (RNA) encoding MurE polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing MurE polypeptides to screen for antibacterial compounds.

Abstract: The present invention provides polypeptide conjugates with reduced allergenicity comprising a polymeric carrier molecule having two or more polypeptide molecules coupled thereto. The invention also provides methods for producing the conjugates, compositions comprising the conjugates, and the use of the conjugates in industrial applications, including personal care products and detergent compositions.

Abstract: Disclosed is a methods for modifying the chain length and double bond positional specificities of a soluble plant fatty acid desaturase. More specifically, the method involves modifying amino acid contact residues in the substrate binding channel of the soluble fatty acid desaturase which contact the fatty acid. Specifically disclosed is the modification of an acyl-ACP desaturase. Amino acid contact residues which lie within the substrate binding channel are identified, and subsequently replaced with different residues to effect the modification of activity.

Abstract: A macromolecular delivery method that utilizes a series of peptides with unique and versatile nuclear targeting properties has been developed, where the peptides are derived from the COOH terminal domain (CTD) of the largest subunit of RNA polymerase II and include heptapeptide units similar or identical to the following consensus sequence: Tyrosine--Serine--Proline--Threonine--Serine--Proline--Serine (YSPTSPS).sub.x (SEQ ID NO. 1). When expressed in vivo, the CTD peptides are phosphorylated and they accumulate in discrete compartments within the nucleus. The CTD peptides concentrate indicator molecules in discrete subnuclear compartments where pre-mRNA molecules are synthesized and spliced. The length and composition of the CTD peptides can be manipulated to obtain different intranuclear partitioning properties. The CTD peptides are functional in the nuclei of S. cerevisiae, S. pombe, nematodes, insects, plants, and all vertebrates.

Abstract: Three classes of GFP mutants having single excitation maxima around 488 nm are brighter than wild-type GFP following 488 nm excitation. GFPmut1 has a double substitution: F64L, S65T; GFPmut2 has a triple substitution: S65A, V68L, S72A; and GFPmut3 is characterized by the double substitution S65G, S72A. The excitation maxima of the three mutants are at 488 nm, 481 nm and 501 nm respectively. The fluorescence intensities following excitation at 488 nm are an order of magnitude higher than that of wild-type GFP excited at 488 nm in E. coli. The expression of GFP is observable minutes after induction.

Abstract: A coryneform bacterium in which a DNA coding for a diaminopimelate decarboxylase and a DNA coding for a diaminopimelate dehydrogenase are enhanced is cultivated in a medium to allow L-lysine to be produced and accumulated in a culture, and L-lysine is collected from the culture.

Abstract: The present invention provides a human RNA editing enzyme (REE-2) and polynucleotides which identify and encode REE-2. The invention also provides expression vectors and host cells, agonists, antibodies, or antagonists. The invention provides methods for producing REE-2 and for treating diseases associated with expression of REE-2.

Abstract: A modified enzyme having a reduced maltopentaose decomposing activity and improvements in practical usability was provided by a gene coding for .alpha.-amylase highly producing maltopentaose, the .alpha.-amylase comprising an amino acid sequence where an amino acid residue at 57- or 139-position has been substituted in the amino acid sequence of maltopentaose-forming amylase derived from Pseudomonas sp. KO-8940 (Shida, O. et al., Biosci. Biotech. Biochem. Vol. 56, 76-80 (1992)).

Abstract: The invention provides a human transducin beta-1 subunit (TBS) and polynucleotides which identify and encode TBS. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating or preventing diseases associated with expression of TBS.

Abstract: The invention relates to a heat-stable pullulanase having the property of hydrolysing glucosidic bonds of the .alpha.-1,6 type in amylopectin and having an enzymatic activity in an acid medium and at a temperature of about 60.degree. C.The invention also relates to strains of microorganisms which produce this pullulanase and processes for the preparation of this pullulanase.The invention also relates to the uses thereof and compositions comprising the product.The invention also relates to a DNA molecule. The invention relates to an expression vector containing this DNA molecule and to a chromosomal integration vector containing this DNA molecule.

Abstract: The present invention relates to hepatitis B virus (hereinafter it refers to HBV) polymerase containing a histidine tag, RNase H enzyme derived from HBV polymerase and processes for preparation thereof. More particularly, the present invention relates to recombinant HBV polymerase, its RNase H domain with enzyme activity, expression vectors producing the enzymes in E. coli and processes for preparing the HBV polymerase and the RNase H enzyme which can be easily purified due to their histidine tags. And the present invention relates to uses of the HBV polymerase and the RNase H enzyme for screening antiviral agents.

Abstract: The present invention provides a novel cellulase composition obtainable from Bacillus sp. CBS 669.93. A preferred cellulase has a calculated molecular weight of approximately 63 kD, a calculated isoelectric point of about 5 and a pH optimum on CMC of about 6 at 40.degree. C. and 60.degree. C.

Abstract: The present invention relates to the single-chain thrombomodulin ("TM") and analogs thereof that are not susceptible to cleavage by proteases and retain the biological activity of thrombomodulin, as well as methods of use in, for example, antithrombotic therapy. Novel proteins, nucleic acid gene sequences, pharmaceuticals and methods of inhibiting thrombotic activity are disclosed.

Abstract: There is disclosed cDNA sequences and polypeptides having the enzyme lysophosphatidic acid acyltransferase (LPAAT) activity. LPAAT is also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.

Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus nidulans. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus nidulans atrC are also provided. The invention further provides assays which utilize these transformed host cells.

Abstract: Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

Abstract: Purified and isolated nucleic acid molecules are provided which encode a dimethylsulfoxide reductase enzyme of a strain of Haemophilus or an individual subunit or a fragment or an analog of the dimethylsulfoxide reductase enzyme. The nucleic acid molecules may be used to produce recombinant dimethylsulfoxide reductase enzyme free of contaminants derived from bacteria normally containing the same for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules may be used in diagnostic applications.

Abstract: The subject invention provides a novel ceramide glucosyltransferase having catalytic activity of glucose transfer from UDP-Glc to ceramide, and a nucleic acid sequence encoding the ceramide glucosyltransferase.

Abstract: The invention relates to ribonucleases derived from a native ribonuclease found in the oocytes of Rana pipiens. Various humanized and recombinant forms of these molecules are described as well as uses for them.

Abstract: The invention provides human fatty acid beta-oxidation enzymes (HUFA) and polynucleotides which identify and encode HUFA. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUFA.